SCHEMBL3672226

SCHEMBL3672226

CC1CCNO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12213960 1.00
Hydrochloric Acid SCHEMBL11077270 0.97
SCHEMBL4135536 0.82
SCHEMBL10238113 0.82
SCHEMBL206350 0.72
SCHEMBL1228334 0.67
SCHEMBL17773098 0.63
SCHEMBL7380649 0.62
SCHEMBL7379165 0.62
SCHEMBL7380085 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220195115-A1 FLUORINE-CONTAINING COPOLYMER DAIKIN INDUSTRIES, LTD. (JP) 2022-06-23 US disclosed
CN-108699053-B 4-hydroxy-2-phenyl-1, 3-thiazol-5-yl methanone derivatives as TRPM8 antagonists 东佩制药股份公司 2022-01-14 CN disclosed
EP-3394053-B1 (4-HYDROXY-2-PHENYL-1,3-THIAZOL-5-YL) METHANONE DERIVATIVES AS TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2019-08-21 EP disclosed
US-10246448-B2 4-hydroxy-2-phenyl-1,3-thiazol-5-yl methanone derivatives as TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2019-04-02 US disclosed
US-20180319785-A1 4-HYDROXY-2-PHENYL-1,3-THIAZOL-5-YL METHANONE DERIVATIVES AS TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-11-08 US disclosed
EP-3394053-A1 4-HYDROXY-2-PHENYL-1,3-THIAZOL-5-YL METHANONE DERIVATIVES AS TRPM8 ANTAGONISTS Dompé farmaceutici S.p.A. (IT) 2018-10-31 EP disclosed
WO-2017108632-A1 4-HYDROXY-2-PHENYL-1,3-THIAZOL-5-YL METHANONE DERIVATIVES AS TRPM8 ANTAGONISTS DOMPE' FARMACEUTICI S.P.A. (IT) 2017-06-29 WO disclosed
US-9540370-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) 2017-01-10 US disclosed
US-20160194320-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS ABBVIE DEUTSCHLAND (DE) 2016-07-07 US disclosed
US-9266855-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2016-02-23 US disclosed
EP-1918286-A1 Thiazolhydrazides for treatment of neurodegenerative diseases MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-07 EP disclosed
EP-1861482-A2 USE OF DIBENZANTHRONE AND ISODIBENZANTHRONE DERIVATIVES AS MARKING SUBSTANCES FOR LIQUIDS BASF AKTIENGESELLSCHAFT (DE) 2007-12-05 EP disclosed
US-20070259881-A1 Substituted Imidazo Ring Systems and Methods COLEY PHARMACEUTICAL GROUP, INC. 2007-11-08 US disclosed
US-20070149415-A1 Power and lubricant additive concentrates containing at least one anthrachinone derivative as a marking substance BASF AKTIENGESELLSCHAFT (DE) 2007-06-28 US disclosed
WO-2006097434-A2 USE OF DIBENZANTHRONE AND ISODIBENZANTHRONE DERIVATIVES AS MARKING SUBSTANCES FOR LIQUIDS BASF AKTIENGESELLSCHAFT (DE) 2006-09-21 WO disclosed
EP-0288515-B1 QUATERNIZED NITROGEN CONTAINING COMPOUNDS ISP INVESTMENTS INC. (US) 1993-05-05 EP disclosed
EP-0288515-A4 QUATERNIZED NITROGEN CONTAINING COMPOUNDS 1990-09-26 EP disclosed
US-4883655-A HAIR OR SKIN CONDITIONING GAF CORPORATION (US) 1989-11-28 US disclosed
EP-0288515-A1 QUATERNIZED NITROGEN CONTAINING COMPOUNDS. GAF CORP (US) 1988-11-02 EP disclosed
WO-1988002985-A1 QUATERNIZED NITROGEN CONTAINING COMPOUNDS GAF CORPORATION (US) 1988-05-05 WO disclosed